Literature DB >> 3184984

Immunological subtypes of acute lymphoblastic leukemia in north India.

M Bhargava1, R Kumar, A Karak, V Kochupillai, L S Arya, T Mohanakumar.   

Abstract

Pretreatment immunologic marker analysis in 152 adult and childhood patients of ALL and ALL/lymphoma employing multiple monoclonal antibodies and hetero-antisera revealed three major subgroups, i.e. T-ALL (37.7%), N-ALL (33.1%) and C-ALL (21.5%). The early age peak was absent, males predominated in all the subgroups and T-ALL had increased incidence of thymic mass. Leucocyte counts of 50,000 X 10(6)/l were equally frequent in the three groups. T-ALL showed marked heterogeneity by showing a variety of markers such as T-helper/inducer, T-suppressor/cytotoxic, p-24, Ia and CALLA. These results show a high prevalence of unfavourable prognostic factors in ALL in our geographic region which might be related to socioeconomic and/or environmental factors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3184984     DOI: 10.1016/0145-2126(88)90102-6

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  4 in total

1.  Lympho-hemopoietic malignancies in India.

Authors:  Manisha Bhutani; Amish Vora; Lalit Kumar; Vinod Kochupillai
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

2.  High mTOR expression independently prognosticates poor clinical outcome to induction chemotherapy in acute lymphoblastic leukemia.

Authors:  Asheema Khanna; Bharat Bhushan; Pradeep Singh Chauhan; Sunita Saxena; Dipendra Kumar Gupta; Fouzia Siraj
Journal:  Clin Exp Med       Date:  2017-10-26       Impact factor: 3.984

3.  Surveillance and expected outcome of acute lymphoblastic leukemia in children and adolescents: An experience from Eastern India.

Authors:  Ashis Mukhopadhyay; Sudeshna Gangopadhyay; Swati Dasgupta; Samrat Paul; Soma Mukhopadhyay; Ujjal Kanti Ray
Journal:  Indian J Med Paediatr Oncol       Date:  2013-10

4.  Analysis of outcomes and prognostic factors of acute lymphoblastic leukemia patients treated by MCP841 protocol: A regional cancer center experience.

Authors:  Akhil Kapoor; Ashok Kalwar; Narender Kumar; Mukesh Kumar Singhal; Surender Beniwal; Harvindra Singh Kumar
Journal:  J Res Med Sci       Date:  2016-03-15       Impact factor: 1.852

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.